More on SPRO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.38 |
|
|||
| Open | $1.38 | ||||
| 52 Wk High | $3.85 | ||||
| 52 Wk Low | $1.25 | ||||
| Day High | $1.38 | ||||
| Day Low | $1.38 | ||||
| P/E | N/A | ||||
| EPS | $-0.28 | ||||
| Volume | 4,223 | ||||
- Form 8-K Spero Therapeutics, Inc. For: Jul 08
- Spero Therapeutics shares fall after $105M KKR deal
- Spero Therapeutics secures $105M royalty-backed financing deal
- Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
- Spero Therapeutics licenses Innovent antibody in deal worth up to $1.1B
- Spero Therapeutics licenses antibody from Innovent in $1.1B deal
- Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
- Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
- Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
- Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Entities mentioned with SPRO
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Cowen & Co | View Related Stories »
- PDUFA | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
